搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
17 小时
RBC维持Ideaya Biosciences目标价,看好daro前景
RBC Capital维持Ideaya Biosciences (NASDAQ:IDYA)的"跑赢大市"评级和61.00美元的目标价。该公司的立场是在审查了公司最近关于其药物候选者darolutamide (daro)监管路径的更新后做出的,特别是考虑到积极的二期数据以及FDA对注册试验设计和终点的认可。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Would-be assassin charged
Gets 2-yrs for role in fraud
Diagnosed with Parkinson's
Phoenix breaks heat record
Woman dies in 'suicide pod’
Contempt charge coming?
‘Trump Train’ jury verdict
Food packaging cancer risk
To shut down TikTok Music
Outlaws guitarist dies
Severe obesity on the rise
Dali owner, operator sued
Retiring after 14 seasons
Executed by lethal injection
Haitian group files complaint
Study about oceans' acidity
Recalls 41K+ motorcycles
Partners with Google
Consumer confidence falls
EEOC blocked on rules
NC sending absentee ballots
X account hacked
1st NL East title since 2011
PA county ballot ruling
Pac-12 sues Mountain West
InfoWars to be auctioned off
ISR: Hezbollah leader killed
Calls for US to lift sanctions
Foreign incentives offer?
Johnny Cash statue unveiled
Won't call special session
反馈